Skip to content
verana-health-logo-inverted
  • Clinicians
    • MIPS Advisory Offerings
    • Practice Insights
    • Verana Trial Connect
    • Verana Quality Measures
  • Life Sciences
    • Clinical Development
    • HEOR & Medical Affairs
    • Commercialization
  • Research
  • Therapeutic Area
    • Oncology
      • Acute Myeloid Leukemia
      • Breast Cancer
      • Chronic Lymphocytic Leukemia
      • Colorectal Cancer
      • Follicular Lymphoma
      • Large B-Cell Lymphoma
      • Lung Cancer
      • Marginal Zone Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Myelodysplastic Syndrome
      • Ovarian Cancer
    • Ophthalmology
      • Anti-VEGF
      • Diabetic Retinopathy
      • Dry Eye Disease
      • Cataracts
      • Geographic Atrophy
      • Glaucoma
      • Neovascular AMD
      • Retinitis Pigmentosa
      • Thyroid Eye Disease
      • Uveitic Macular Edema
      • Qdata Explorer
    • Urology
      • Benign Prostatic Hyperplasia
      • Bladder Cancer
      • Prostate Cancer
    • Neurology
      • Multiple Sclerosis
      • Parkinson’s Disease
      • Spinal Muscular Atrophy
  • Solutions
    • Clinical Research Solutions
      • Trial Design
      • Protocol Optimization & Site Selection
      • Patient Recruitment
      • Prospective Evidence Generation (PEG)
    • Clinical Trials
      • Site Explorer
    • Market Insights
      • Market Tracking
      • Brand Switching
      • Prescriber Mapping
    • RWE Studies
      • Patient Segmentation
      • Safety Studies
      • Natural History of Disease / Disease Progression
      • Comparative Effectiveness
      • Treatment Patterns & Outcomes
      • Healthcare Resource Utilization (HCRU) Cost
    • Phase IV Studies / Surveillance
  • About Us
    • About
      • Evolve Registry
    • Team
    • Press
    • Blog
    • Careers
    • Partners
      • Societies
      • CROs
      • Technology and Data
    • Privacy
      • Privacy Policy
      • Patient Privacy
Contact Us

Contemporary Trends of Benign Prostatic Hyperplasia Procedures in the AUA Quality Registry: Are We Moving the Needle Toward More Minimally Invasive Treatments?

Read More

A Multifaceted Assessment of Benign Prostatic Hyperplasia Practice and AUA Guideline Adherence

Read More

Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry

Read More

Choice of First Medication Prescribed For Overactive Bladder Changes With Time: Trends From The AUA AQUA Registry

Read More

Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry

Read More

Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US

Read More

Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration

Read More

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema”

Read More

Functional Outcomes and Quality of Life in Geographic Atrophy in the Clinical Setting

Read More

Long-term Treatment Patterns for Diabetic Macular Edema

Read More
Older Posts »

Recent Posts

  • Verana Health Delivers Powerful Update to RWD Bladder Cancer Database
  • Verana Health Introduces Expanded Ovarian Cancer Dataset
  • Verana Health Transforms Site Selection and Patient Enrollment in Clinical Trials
  • Verana Health Introduces World’s Largest Real-World Dataset for Prostate Cancer
  • New Verana Health AI Agent Boosts Efficiency and Compliance in MIPS Submissions
verana-health-logo-inverted

© 2026 Verana Health. All Rights Reserved.

San Francisco
New York
Knoxville
  • Privacy Policy
  • Cookie Policy
Back to Top